Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation.

Kerr CL, Bol GM, Vesuna F, Raman V.

Genes Cancer. 2019 Feb;10(1-2):11-20. doi: 10.18632/genesandcancer.187.

2.

Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33.

Tantravedi S, Vesuna F, Winnard PT Jr, Martin A, Lim M, Eberhart CG, Berlinicke C, Raabe E, van Diest PJ, Raman V.

Transl Oncol. 2019 Jan;12(1):96-105. doi: 10.1016/j.tranon.2018.09.002. Epub 2018 Oct 3.

3.

Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach.

Heerma van Voss MR, Kammers K, Vesuna F, Brilliant J, Bergman Y, Tantravedi S, Wu X, Cole RN, Holland A, van Diest PJ, Raman V.

Transl Oncol. 2018 Jun;11(3):755-763. doi: 10.1016/j.tranon.2018.04.001. Epub 2018 Apr 24.

4.

Role of DDX3 in the pathogenesis of inflammatory bowel disease.

Tantravedi S, Vesuna F, Winnard PT Jr, Van Voss MRH, Van Diest PJ, Raman V.

Oncotarget. 2017 Dec 15;8(70):115280-115289. doi: 10.18632/oncotarget.23323. eCollection 2017 Dec 29.

5.

Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.

Heerma van Voss MR, Vesuna F, Bol GM, Afzal J, Tantravedi S, Bergman Y, Kammers K, Lehar M, Malek R, Ballew M, Ter Hoeve N, Abou D, Thorek D, Berlinicke C, Yazdankhah M, Sinha D, Le A, Abrahams R, Tran PT, van Diest PJ, Raman V.

Oncogene. 2018 Jan 4;37(1):63-74. doi: 10.1038/onc.2017.308. Epub 2017 Sep 4.

6.

Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer.

Heerma van Voss MR, Vesuna F, Bol GM, Meeldijk J, Raman A, Offerhaus GJ, Buerger H, Patel AH, van der Wall E, van Diest PJ, Raman V.

Onco Targets Ther. 2017 Jul 17;10:3501-3513. doi: 10.2147/OTT.S140639. eCollection 2017.

7.

Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes.

Winnard PT Jr, Zhang C, Vesuna F, Kang JW, Garry J, Dasari RR, Barman I, Raman V.

Oncotarget. 2017 Mar 21;8(12):20266-20287. doi: 10.18632/oncotarget.14865.

8.

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.

Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.

9.

Genomic pathways modulated by Twist in breast cancer.

Vesuna F, Bergman Y, Raman V.

BMC Cancer. 2017 Jan 13;17(1):52. doi: 10.1186/s12885-016-3033-3.

10.

RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.

Xie M, Vesuna F, Tantravedi S, Bol GM, Heerma van Voss MR, Nugent K, Malek R, Gabrielson K, van Diest PJ, Tran PT, Raman V.

Cancer Res. 2016 Nov 1;76(21):6340-6350. Epub 2016 Sep 12.

11.

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.

Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.

12.

NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.

Xie M, Vesuna F, Botlagunta M, Bol GM, Irving A, Bergman Y, Hosmane RS, Kato Y, Winnard PT Jr, Raman V.

Oncotarget. 2015 Oct 6;6(30):29901-13. doi: 10.18632/oncotarget.4898.

13.

Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.

Heerma van Voss MR, Vesuna F, Trumpi K, Brilliant J, Berlinicke C, de Leng W, Kranenburg O, Offerhaus GJ, Bürger H, van der Wall E, van Diest PJ, Raman V.

Oncotarget. 2015 Sep 29;6(29):28312-26. doi: 10.18632/oncotarget.4873.

14.

Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.

Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, van der Groep P, Kondaskar A, Rudek MA, Hosmane RS, van der Wall E, van Diest PJ, Tran PT, Raman V.

EMBO Mol Med. 2015 May;7(5):648-69. doi: 10.15252/emmm.201404368.

15.

The twist box domain is required for Twist1-induced prostate cancer metastasis.

Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT.

Mol Cancer Res. 2013 Nov;11(11):1387-400. doi: 10.1158/1541-7786.MCR-13-0218-T. Epub 2013 Aug 27.

16.

The transcription factor encyclopedia.

Yusuf D, Butland SL, Swanson MI, Bolotin E, Ticoll A, Cheung WA, Zhang XY, Dickman CT, Fulton DL, Lim JS, Schnabl JM, Ramos OH, Vasseur-Cognet M, de Leeuw CN, Simpson EM, Ryffel GU, Lam EW, Kist R, Wilson MS, Marco-Ferreres R, Brosens JJ, Beccari LL, Bovolenta P, Benayoun BA, Monteiro LJ, Schwenen HD, Grontved L, Wederell E, Mandrup S, Veitia RA, Chakravarthy H, Hoodless PA, Mancarelli MM, Torbett BE, Banham AH, Reddy SP, Cullum RL, Liedtke M, Tschan MP, Vaz M, Rizzino A, Zannini M, Frietze S, Farnham PJ, Eijkelenboom A, Brown PJ, Laperrière D, Leprince D, de Cristofaro T, Prince KL, Putker M, del Peso L, Camenisch G, Wenger RH, Mikula M, Rozendaal M, Mader S, Ostrowski J, Rhodes SJ, Van Rechem C, Boulay G, Olechnowicz SW, Breslin MB, Lan MS, Nanan KK, Wegner M, Hou J, Mullen RD, Colvin SC, Noy PJ, Webb CF, Witek ME, Ferrell S, Daniel JM, Park J, Waldman SA, Peet DJ, Taggart M, Jayaraman PS, Karrich JJ, Blom B, Vesuna F, O'Geen H, Sun Y, Gronostajski RM, Woodcroft MW, Hough MR, Chen E, Europe-Finner GN, Karolczak-Bayatti M, Bailey J, Hankinson O, Raman V, LeBrun DP, Biswal S, Harvey CJ, DeBruyne JP, Hogenesch JB, Hevner RF, Héligon C, Luo XM, Blank MC, Millen KJ, Sharlin DS, Forrest D, Dahlman-Wright K, Zhao C, Mishima Y, Sinha S, Chakrabarti R, Portales-Casamar E, Sladek FM, Bradley PH, Wasserman WW.

Genome Biol. 2012;13(3):R24. doi: 10.1186/gb-2012-13-3-r24.

17.

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.

Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE, Bhujwalla ZM, Gribbestad IS, Glunde K.

NMR Biomed. 2012 Sep;25(9):1033-42. doi: 10.1002/nbm.2766. Epub 2012 Jan 26.

18.

Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.

Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P, Raman V.

Oncogene. 2012 Jul 5;31(27):3223-34. doi: 10.1038/onc.2011.483. Epub 2011 Nov 7.

19.

Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Kondaskar A, Kondaskar S, Kumar R, Fishbein JC, Muvarak N, Lapidus RG, Sadowska M, Edelman MJ, Bol GM, Vesuna F, Raman V, Hosmane RS.

ACS Med Chem Lett. 2010 Dec 31;2(3):252-256.

20.

Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells.

Botlagunta M, Krishnamachary B, Vesuna F, Winnard PT Jr, Bol GM, Patel AH, Raman V.

PLoS One. 2011 Mar 23;6(3):e17563. doi: 10.1371/journal.pone.0017563.

21.

Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.

Vesuna F, Lisok A, Kimble B, Raman V.

Neoplasia. 2009 Dec;11(12):1318-28.

22.
23.

Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.

Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM.

Oncogene. 2009 Aug 20;28(33):2940-7. doi: 10.1038/onc.2009.180. Epub 2009 Jul 6.

24.

Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model.

Winnard PT Jr, Botlagunta M, Kluth JB, Mukadam S, Krishnamachary B, Vesuna F, Raman V.

Cancer Gene Ther. 2008 Oct;15(10):645-54. doi: 10.1038/cgt.2008.39. Epub 2008 Jun 13.

25.

Oncogenic role of DDX3 in breast cancer biogenesis.

Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P Jr, Mukadam S, Van Diest P, Chen JH, Farabaugh P, Patel AH, Raman V.

Oncogene. 2008 Jun 26;27(28):3912-22. doi: 10.1038/onc.2008.33. Epub 2008 Feb 11.

26.

Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model.

Glunde K, Shah T, Winnard PT Jr, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM.

Cancer Res. 2008 Jan 1;68(1):172-80. doi: 10.1158/0008-5472.CAN-07-2678.

27.

Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer.

Vesuna F, van Diest P, Chen JH, Raman V.

Biochem Biophys Res Commun. 2008 Mar 7;367(2):235-41. Epub 2007 Dec 4.

28.

Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models.

Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D.

Cancer Biol Ther. 2007 Jun;6(6):891-7. Epub 2007 Mar 5.

29.

Histamine: a potential therapeutic agent for breast cancer treatment?

Vesuna F, Raman V.

Cancer Biol Ther. 2006 Nov;5(11):1472-3. Epub 2006 Nov 15. No abstract available.

30.

HOXA5 regulates hMLH1 expression in breast cancer cells.

Duriseti S, Winnard PT Jr, Mironchik Y, Vesuna F, Raman A, Raman V.

Neoplasia. 2006 Apr;8(4):250-8.

31.

Twist overexpression promotes chromosomal instability in the breast cancer cell line MCF-7.

Vesuna F, Winnard P Jr, Glackin C, Raman V.

Cancer Genet Cytogenet. 2006 Jun;167(2):189-91. No abstract available. Erratum in: Cancer Genet Cytogenet. 2006 Nov;171(1):81.

32.

Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.

Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, Burger H, Glackin C, Raman V.

Cancer Res. 2005 Dec 1;65(23):10801-9.

33.

Enhanced green fluorescent protein as an alternative control reporter to Renilla luciferase.

Vesuna F, Winnard P Jr, Raman V.

Anal Biochem. 2005 Jul 15;342(2):345-7. No abstract available.

34.

Detection and evaluation of non-recombinants in cDNA libraries by multiple cloning region PCR.

Bandyopadhyay D, Vesuna FD.

Biotechniques. 2002 Jan;32(1):88-90, 92.

Supplemental Content

Loading ...
Support Center